CN102028834B - 一种复方龙血竭制剂及其制备方法 - Google Patents
一种复方龙血竭制剂及其制备方法 Download PDFInfo
- Publication number
- CN102028834B CN102028834B CN201010555272XA CN201010555272A CN102028834B CN 102028834 B CN102028834 B CN 102028834B CN 201010555272X A CN201010555272X A CN 201010555272XA CN 201010555272 A CN201010555272 A CN 201010555272A CN 102028834 B CN102028834 B CN 102028834B
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- longxuejie
- sanguis draxonis
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- 150000001875 compounds Chemical class 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 241000180649 Panax notoginseng Species 0.000 claims description 35
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 35
- 239000009286 sanguis draxonis Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 21
- 241001043298 Croton draco Species 0.000 description 19
- 239000009136 dragon's blood Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 11
- 230000002526 effect on cardiovascular system Effects 0.000 description 11
- 229940039009 isoproterenol Drugs 0.000 description 11
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 208000026106 cerebrovascular disease Diseases 0.000 description 10
- 208000005189 Embolism Diseases 0.000 description 9
- 208000001435 Thromboembolism Diseases 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 230000002537 thrombolytic effect Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 206010041956 Stasis syndrome Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000005634 blind loop syndrome Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000292342 Dracaena cochinchinensis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010555272XA CN102028834B (zh) | 2010-11-23 | 2010-11-23 | 一种复方龙血竭制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010555272XA CN102028834B (zh) | 2010-11-23 | 2010-11-23 | 一种复方龙血竭制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102028834A CN102028834A (zh) | 2011-04-27 |
CN102028834B true CN102028834B (zh) | 2012-07-04 |
Family
ID=43882644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010555272XA Active CN102028834B (zh) | 2010-11-23 | 2010-11-23 | 一种复方龙血竭制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102028834B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784683B (zh) * | 2014-01-24 | 2016-08-17 | 江苏康缘药业股份有限公司 | 一种治疗肥胖症的中药组合物及其制备方法和应用 |
CN106853148A (zh) * | 2016-01-05 | 2017-06-16 | 云南大唐汉方制药股份有限公司 | 复方龙血竭制剂及其制备方法 |
CN106421293B (zh) * | 2016-12-06 | 2019-02-26 | 昆药集团股份有限公司 | 一种治疗心脑血管疾病的中药有效部位组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255151C (zh) * | 2003-04-25 | 2006-05-10 | 云南云河药业有限公司 | 复方龙血竭及其制备方法 |
CN101085134A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 一种含血竭治疗心血管疾病的组合物及其制剂 |
-
2010
- 2010-11-23 CN CN201010555272XA patent/CN102028834B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255151C (zh) * | 2003-04-25 | 2006-05-10 | 云南云河药业有限公司 | 复方龙血竭及其制备方法 |
CN101085134A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 一种含血竭治疗心血管疾病的组合物及其制剂 |
Non-Patent Citations (1)
Title |
---|
庆慧等.复方龙血竭胶囊治疗稳定型心绞痛随机对照多中心临床研究.《中国中医药信息杂志》.2009,第16卷(第2期),第10-12页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102028834A (zh) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104688822A (zh) | 一种辅助降血糖片及制备方法 | |
CN102512521A (zh) | 一种治疗中风后遗症的中药组合物 | |
CN103405655B (zh) | 一种降糖的中药组合物及其制备方法 | |
CN102028834B (zh) | 一种复方龙血竭制剂及其制备方法 | |
CN102579560A (zh) | 当归黄芪合剂水提物的制备方法及干预肺纤维化的应用 | |
CN102579836A (zh) | 一种霍山石斛中药组合物及其制备方法 | |
CN101849987B (zh) | 当归黄芪合剂醇提物与水提物制备及干预肺纤维化的应用 | |
CN103223104A (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN102357134B (zh) | 用于预防和治疗阿尔茨海默病及脑血栓的药物及其制备方法 | |
CN106668348A (zh) | 用于治疗糖尿病视网膜病变的药物组合物 | |
CN103385931B (zh) | 一种降血糖的药物组合物 | |
CN101411850B (zh) | 一种治疗气虚血瘀型脑中风的中药组合物、中药制剂及其制备方法 | |
CN102961517B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN108704070A (zh) | 一种中西药结合的治疗糖尿病的药物 | |
CN101254248B (zh) | 一种中药组合物在制备治疗慢性疲劳综合症药物中的应用 | |
CN101032534B (zh) | 救必应总皂苷的制备方法及应用 | |
CN100542548C (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN100430072C (zh) | 一种治疗心脑血管疾病中药制剂 | |
CN101716253B (zh) | 一种活血化淤、益气养阴的中药制剂及其制备方法 | |
CN103800449B (zh) | 一种治疗阴虚热盛证2型糖尿病的中药组合物 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
CN103356731A (zh) | 含有杜仲提取物与三七总皂苷的血塞通片及其应用 | |
CN103263581A (zh) | 用于降血糖的双参胶囊 | |
TWI844079B (zh) | 中藥組合物及其製備方法和應用 | |
CN103417906A (zh) | 复方斑蝥中药组合物及其制剂在制备治疗抑郁症药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YUNNAN YUNHE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YUNHE PHARAMCEUTICAL CO., LTD., YUNNAN |
|
CP03 | Change of name, title or address |
Address after: 661000, No. 1, Yunhe Road, Gejiu City, Yunnan Patentee after: YUNNAN YUNHE PHARMACEUTICALS Inc. Address before: 661000 old Yangshan, Gejiu City, Yunnan Patentee before: Yunnan Yunhe Pharmaceuticals Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Longxueji preparation and preparation method thereof Effective date of registration: 20160328 Granted publication date: 20120704 Pledgee: Yunnan Yunyao Industry Group Co. Ltd Pledgor: YUNNAN YUNHE PHARMACEUTICALS INC. Registration number: 2016990000135 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170210 Granted publication date: 20120704 Pledgee: Yunnan Yunyao Industry Group Co. Ltd Pledgor: YUNNAN YUNHE PHARMACEUTICALS INC. Registration number: 2016990000135 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Longxueji preparation and preparation method thereof Effective date of registration: 20170711 Granted publication date: 20120704 Pledgee: Yunnan Finance Leasing (Shanghai) Co.,Ltd. Pledgor: YUNNAN YUNHE PHARMACEUTICALS INC. Registration number: 2017530000010 |
|
CI03 | Correction of invention patent | ||
CI03 | Correction of invention patent |
Correction item: Pledgee of the pledge contract Correct: Yun energy financing lease (Shanghai) Co., Ltd. False: Yunnan finance lease (Shanghai) Co., Ltd. Number: 31-02 Volume: 33 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210719 Granted publication date: 20120704 Pledgee: Yun energy financing lease (Shanghai) Co.,Ltd. Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: 2017530000010 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a compound dragon's blood preparation and a preparation method thereof Effective date of registration: 20220224 Granted publication date: 20120704 Pledgee: Gejiu Rural Credit Cooperative Association Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: Y2022530000007 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20120704 Pledgee: Gejiu Rural Credit Cooperative Association Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: Y2022530000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound dragon's blood preparation and its preparation method Granted publication date: 20120704 Pledgee: Gejiu Rural Credit Cooperative Association Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: Y2024980011745 |